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Abstract: Obesity, insulin resistance, hypertension and fatty liver, together termed 
metabolic syndrome, are key risk factors for cardiovascular disease. Chronic feeding of a 
diet high in saturated fats and simple sugars, such as fructose and glucose, induces these 
changes in rats. Naturally occurring compounds could be a cost-effective intervention to 
reverse these changes. Flavonoids are ubiquitous secondary plant metabolites; naringin 
gives the bitter taste to grapefruit. This study has evaluated the effect of naringin on  
diet-induced obesity and cardiovascular dysfunction in high carbohydrate, high fat-fed rats. 
These rats developed increased body weight, glucose intolerance, increased plasma lipid 
concentrations, hypertension, left ventricular hypertrophy and fibrosis, liver inflammation 
and steatosis with compromised mitochondrial respiratory chain activity. Dietary 
supplementation with naringin (approximately 100 mg/kg/day) improved glucose 
intolerance and liver mitochondrial dysfunction, lowered plasma lipid concentrations and 
improved the structure and function of the heart and liver without decreasing total body 
weight. Naringin normalised systolic blood pressure and improved vascular dysfunction 
and ventricular diastolic dysfunction in high carbohydrate, high fat-fed rats. These 
beneficial effects of naringin may be mediated by reduced inflammatory cell infiltration, 
reduced oxidative stress, lowered plasma lipid concentrations and improved liver 
mitochondrial function in rats. 
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1. Introduction 
Metabolic syndrome is defined as a collection of risk factors for cardiovascular disease, including 
abdominal obesity, hypertension, insulin resistance and fatty liver. This syndrome is associated with an 
increased dietary intake of saturated fats and simple sugars, including glucose and fructose [1,2]. The 
prevalence of metabolic syndrome is increasing throughout the world [1], suggesting that more can be 
done to provide affordable treatment options. These options include local natural products, as they 
could be readily available at low cost, with an appropriate safety profile, as they may have been 
available in foods for many generations. The flavonoids are ubiquitous as secondary metabolites in 
plants. Experimental and epidemiological data indicate that dietary flavonoids reduced the risk of 
coronary heart disease, diabetes and non-alcoholic fatty liver diseases [3], so these compounds are 
potential options for treatment of metabolic syndrome.  
Naringin (4′,5,7-trihydroxyflavone 7-rhamnoglucoside), found in grape fruit and related citrus 
species [3], and its colonic metabolite, naringenin, have been reported to show anti-inflammatory, 
antioxidant and cardioprotective activities, including lowering of blood glucose and cholesterol 
concentrations and improved insulin signalling [4–8]. Naringin upregulated peroxisome  
proliferator-activated receptor γ (PPARγ) [8], activated adenosine monophosphate (AMP) kinase [9] 
and suppressed liver fatty acid synthase, glucose-6-phosphate dehydrogenase, phosphatidate 
phosphohydrolase, HMG-CoA reductase and acyl CoA:cholesterol acyltransferase activities in type 2 
diabetic mice [10].  
We have reported that rats fed a high carbohydrate, high fat diet for 16 weeks developed many of 
the signs of metabolic syndrome in humans [11]. Further, chronic treatment with the flavonoid,  
rutin [12], or its aglycone, quercetin [13], reversed most of these symptoms, despite continuation of the 
high carbohydrate, high fat diet. The present study has determined whether administration of naringin 
at the same dose as rutin [12] reverses the metabolic parameters, as well as the changes in the structure 
and function of the heart, blood vessels, liver and kidneys in rats fed a high carbohydrate, high fat diet. 
We suggest that naringin has the potential to be a useful dietary supplement in the management of the 
signs of metabolic syndrome. 
2. Experimental Section  
2.1. Rats and Diets 
Male Wistar rats (n = 36; 328 ± 1 g; 9–10 weeks old) were purchased from The University of 
Queensland Biological Resources facility. They were individually caged at the Faculty of Sciences 
Animal House at the University of Southern Queensland. All experimental protocols were approved by 
the Animal Experimentation Ethics Committee of the University of Southern Queensland, under the 
guidelines of the National Health and Medical Research Council of Australia. The rats were randomly 
divided into four separate groups: cornstarch (C; n = 9), C + naringin (N) (CN; n = 9), high 
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carbohydrate, high fat diet (H; n = 9) and H + N (HN; n = 9). C and H rats were fed their respective 
diets throughout the 16-week protocol (Table 1). Drinking water in the H diet-fed rats was augmented 
with 25% fructose. The H diet was prepared by thoroughly mixing beef tallow, condensed milk, 
powdered rat feed (meat-free rat and mouse feed, Specialty Feeds) and Hubble, Mendel and Wakeman 
salt mixture (MP Biochemicals) [11]. In the C diet, fructose and condensed milk were replaced with 
corn starch (575 g) and beef tallow was replaced with water (200 mL). N was thoroughly mixed with 
both C and H diets at 1.6 g/kg to give an approximate dose of 100 mg/kg/day; N was administered for  
8 weeks starting 8 weeks after the initiation of either diet.  
Organ weights, metabolic measurements (plasma glucose, insulin and lipid concentrations, 
abdominal circumference and abdominal fat pads), cardiovascular evaluations (systolic blood  
pressure, echocardiography, left ventricular stiffness in the Langendorff heart preparation, thoracic 
aortic ring reactivity, collagen deposition and inflammatory cell infiltration) and liver  
measurements (plasma enzymes, liver structure) were determined, as described previously [11–14]. 
Malondialdehyde concentrations were measured as thiobarbituric acid reactive substances by UV  
spectrophotometry [15]. 
2.2. Mitochondrial Preparations 
Mitochondria were isolated from the liver of rats according to standard differential centrifugation 
procedures [16] and prepared in a medium containing 200 mM sucrose, 1 mM ethylene glycol 
tetraacetic acid (EGTA) and 10 mM Tris-HCl (pH 7.2). Mitochondrial protein content was determined 
by the bicinchoninic acid protein assay method, with bovine serum albumin (BSA) as the standard. 
Mitochondria were incubated at a final concentration of 0.35 mg/ml in a Clark-type electrode chamber 
for oxygen consumption measurements. All experiments were performed at 37 °C in a buffer 
containing 125 mM KCl, 1 mM EGTA, 1 mM KH2PO4 and 10 mM Tris-HCl (pH 7.2). The control 
(non-phosphorylating) state of respiration was initiated by the addition of 5 mM succinate/5 µM 
rotenone. State 3 (phosphorylating respiration) was obtained after the addition of 1 mM adenosine 
diphosphate (ADP). State 4 respiration was considered as the respiratory state in the absence of ADP. 
The efficiency of the mitochondrial oxidative phosphorylation was assessed by the state 3 to state 4 
ratio, the respiratory control ratio (RCR). 
2.3. Histology 
Immediately after euthanasia, the heart and liver were blotted, weighed and cut into 3–4 mm slices, 
then fixed in 10% buffered formalin for 3 days, with a change of formalin solution every day to 
remove traces of tissue debris. The samples were then dehydrated and embedded in paraffin wax. Thin 
sections (5 µm) were cut and stained with either haematoxylin and eosin stain for determination of 
inflammatory cell infiltration and general architecture of the tissues or picrosirius red stain in the left 
ventricle or Milligan’s trichrome in the liver for collagen distribution. Collagen distribution was 
analysed by laser confocal microscopy (Zeiss LSM 510 upright Confocal Microscope). Colour 
intensity was quantitated using NIH-ImageJ free software (NIH) to determine the extent of collagen 
deposition in selected tissue sections. 
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2.4. Statistical Analysis  
All data sets were represented as the mean ± standard error of mean (SEM). Comparisons of 
findings between groups were made via statistical analysis of data sets using one-way and two-way 
analysis of variance (ANOVA). When interaction and/or the main effects were significant, means were 
compared using Newman-Keuls multiple-comparison post-hoc test. A p-value of <0.05 was considered 
as statistically significant. All statistical analyses were performed using Graph Pad Prism version 5.00  
for Windows. 
3. Results  
3.1. Metabolic Parameters 
Food intake was higher in the C group compared to the H group, but energy intake was higher in H 
rats. This increase was associated with an increased final body weight, abdominal circumference and 
abdominal fat deposition compared with C rats (Table 1). Based on daily food measurements, N intake 
was 115.4 ± 1.9 mg/kg/day (n = 9) in CN rats and 95.4 ± 2.2 mg/kg/day in N rats. N did not alter the 
food and energy intake in either C or H rats, and body weight in CN and HN rats was not different 
from C and H rats, respectively (Table 1). N reduced retroperitoneal abdominal fat deposition and 
attenuated the increased abdominal circumference in H rats without changing omental or epididymal 
fat pads (Table 1).  
Basal blood glucose and plasma total cholesterol, triglyceride and non-essential fatty acid (NEFA) 
concentrations were increased in H diet-fed rats compared to C group rats (Table 2). N 
supplementation to H rats for the final eight weeks reduced plasma lipid concentrations (Table 2) and 
improved oral glucose tolerance (Table 1). Insulin concentrations and pancreatic wet weights were 
increased in H rats compared to C rats and nomalised by N (Tables 1 and 2).  
Table 1. Naringin on body weights, food and water intakes and organ wet weights. 
Parameters C CN H HN 
p value 
Diet Treatment Interaction
Initial body weight, g 330 ± 3 327 ± 2 327 ± 3 327 ± 2 0.56 0.56 0.56 
Final body weight, g 451 ± 13 b 472 ± 12 ab 509 ± 6 a 503 ± 14 a 0.0006 0.53 0.26 
% of weight gain at week 16 8.3 ± 1.1 b 7.6 ± 1.5 b 13.6 ± 1.6 a 13.4 ± 1.5 a 0.0004 0.81 0.92 
Food intake at week 16, g/day 33.4 ± 0.7 a 32.2 ± 0.4 a 28.0 ± 1.1 b 28.1 ± 0.8 b <0.0001 0.49 0.42 
Water intake at week 16, 
mL/day 
31.9 ± 3.4 a 34.3 ± 0.8 a 22.8 ± 1.4 b 28.7 ± 0.6 a 0.0005 0.37 0.37 
Energy intake at week 16, 
kJ/day 
407 ± 9 a 396 ± 5 a 590 ± 20 b 603 ± 11 b <0.0001 0.94 0.35 
Kidney weight, mg/mm 47.0 ± 1.5 c 57.8 ± 1.6 a 55.5 ± 2.7 ab 55.1 ± 1.2 ab 0.1 0.0075 0.0032 
Spleen, mg/mm 17.1 ± 0.7 19.1 ± 0.9 20.8 ± 2.3 19.4 ± 0.6 0.14 0.82 0.21 
Liver wet weight, mg/mm 243.5 ± 5.4 a 297.9 ± 11.5 c 339.0 ± 14.2 b 289.7 ± 8.5 c 0.0002 0.81 <0.0001 
Abdominal fat pads, mg/mm 449.2 ± 37.3 b 382.0 ± 46.1 b 730.3 ± 34.3 a 695.8 ± 70.0 a <0.0001 0.31 0.74 
Retroperitoneal fat, mg/mm 266.0 ± 21.9 b 188.2 ± 21.3 c 422.9 ± 18.7 a 350.8 ± 37.0 a <0.0001 0.0072 0.92 
Epididymal fat, mg/mm 97.4 ± 13.4 b 97.5 ± 11.3 b 173.4 ± 15.7 a 167.7 ± 15.2 a <0.0001 0.84 0.84 
Omental fat, mg/mm 85.8 ± 6.7 b 96.2 ± 15.2 b 134.0 ± 12.8 b 177.3 ± 21.2 a 0.0002 0.08 0.28 
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Table 1. Cont. 
Abdominal circumference at 
16 weeks, cm 
21.7 ± 0.3 bc 21.2 ± 0.3 c 23.8 ± 0.15 a 22.3 ± 0.2 b <0.0001 0.0004 0.05 
Pancreas wet weight, mg/mm 45.3 ± 1.9 b 47.0 ± 3.9 b 60.8 ± 2.9 a 50.0 ± 0.4 b 0.0014 0.09 0.0239 
Oral glucose tolerance test (area under curve) 
Area under curve (AUC) at  
0 week 
683 ± 21 679 ± 19 671 ± 18 684 ± 20 0.85 0.84 0.68 
AUC at 8 weeks 682 ± 12 a 700 ± 12 a 802 ± 19 b 781 ± 16 b <0.0001 0.91 0.21 
AUC at 16 weeks 707 ± 8 b 687 ± 21 b 854 ± 18 a 709 ± 18 b <0.0001 <0.0001 0.0011 
Data are presented as the mean ± SEM, n = 8–9. C = cornstarch; CN = C + naringin (N); H = high carbohydrate, high fat diet;  
HN = H + N; AUC (area under curve) is the value under the blood glucose curve from 0 to 120 min after glucose administration. Means 
without a common letter in rows are significantly different at p < 0.05. 
Table 2. Naringin on plasma parameters in C and H-diet fed rats. 
Parameters C CN H HN 
p values 
Diet Treatment Interaction
ALT, U/L 28.4 ± 4.1 b 33.8 ± 1.0 ab 41.9 ± 2.1 a 37.5 ± 2.3 ab 0.0028 0.85 0.07 
AST, U/L 68.6 ± 3.5 b 67.8 ± 4.1 b 84.4 ± 5.9 a 72.8 ± 2.7 ab 0.0201 0.15 0.21 
Triglycerides, mmol/L 0.6 ± 0.1 1.2 ± 0.2 1.4 ± 0.4 1.6 ± 0.3 0.0369 0.16 0.47 
Total cholesterol, mmol/L 1.6 ± 0.1 b 1.7 ± 0.1 b 2.2 ± 0.1 a 1.6 ± 0.1 b 0.0186 0.0186 0.0016 
NEFA, mmol/L 1.4 ± 0.2 b 0.7 ± 0.1 b 3.8 ± 0.7 a 0.8 ± 0.1 b 0.0022 <0.0001 0.0044 
Uric acid, mmol/L 46.7 ± 1.8 a 29.6 ± 2.1 b 49.0 ± 2.1 a 43.9 ± 5.9 a 0.022 0.0031 0.09 
Insulin, μmol/L 1.9 ± 0.2 b 2.2 ± 0.5 b 4.2 ± 0.8 a 1.7 ± 0.2 b 0.08 0.0337 0.0083 
Plasma TBARS, µmol/L 12.4 ± 1.3 b 14.4 ± 0.9 b 37.4 ± 6.1 a 17.1 ± 1.8 b 0.0097 0.0004 0.0025 
Data are presented as the mean ± SEM, n = 6–8. ALT = alanine transaminase; AST = aspartate transaminase;  
TBARS = thiobarbituric acid reactive substance. Means without a common letter in rows are significantly different at  
p < 0.05. 
3.2. Cardiovascular Structure and Function 
Systolic blood pressure was increased in the H group compared to C group rats. N reduced the 
systolic blood pressure in H rats (Figure 1). Echocardiographic assessment of H rats showed increased 
left ventricular internal diameter in diastole (LVIDd), reduced fractional shortening and ejection 
fraction, created greater relative wall thickness, increased estimated left ventricle (LV) mass and 
reduced E:A ratio (early:late (or atrial) flow through mitral valve) compared with the C group  
(Table 3). N normalised the LVIDd in H diet fed rats and improved fractional shortening without 
changing ejection fraction, relative wall thickness or E:A ratio (Table 3). Ex vivo cardiac function 
measured in the Langendorff isolated heart preparation showed markedly increased cardiac stiffness in 
H rats compared to C group rats that was normalised by N (Table 3). H diet-fed rats developed 
increased LV wet weight compared to C rats that were normalised by N (Table 3). Neither diet nor 
treatment affected the right ventricle (RV) wet weight (Table 3).  
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Figure 1. Effect of naringin on systolic blood pressure. Time course of tail cuff systolic 
blood pressure of Wistar rats given C, CN, H and HN (n = 9 in each group). Means without 
a common letter are significantly different at p < 0.05. 
 
Table 3. Naringin on cardiovascular parameters. 
Parameters C CN H HN 
p value 
Diet Treatment Interaction 
LVIDd, mm 7.14 ± 0.16 b 7.59 ± 0.18 ab 8.35 ± 0.26 a 7.62 ± 0.21 ab <0.0001 <0.0001 <0.0001 
LVPWd, mm 1.84 ± 0.03 b 1.94 ± 0.12 b 2.22 ± 0.05 a 1.92 ± 0.05 b 0.0215 0.18 0.0116 
Fractional shortening, % 48.2 ± 1.2 a 56.4 ± 4.9 a 35.7 ± 1.2 b 48.3 ± 2.8 a 0.0021 0.002 0.47 
Ejection fraction, % 90.7 ± 1.2 b 89.4 ± 1.5 b 96.5 ± 0.3 a 92.5 ± 1.3 b 0.001 0.0312 0.26 
Relative wall thickness 0.49 ± 0.01 a 0.57 ± 0.06 b 0.49 ± 0.01 a 0.50 ± 0.02 a 0.08 0.0296 0.08 
Ascending aortic flow, m/s 0.86 ± 0.02 0.98 ± 0.13 1.08 ± 0.05 0.82 ± 0.08 0.7 0.37 0.0203 
Descending aortic flow, m/s 0.79 ± 0.6 0.73 ± 0.8 0.96 ± 0.7 0.77 ± 0.7 0.15 0.09 0.36 
E:A ratio 1.9 ± 0.2 - * 1.4 ± 0.2 1.7 ± 0.4 - - - 
Ejection time, ms 87.3 ± 1.5 a 69.3 ± 8.6 b 77.0 ± 2.8 ab 81.8 ± 2.7 ab 0.81 0.16 0.0187 
Deceleration time, ms 58.5 ± 1.9 a 37.9 ± 3.6 b 45.4 ± 2.9 b 47.0 ± 3.8 b 0.06 0.0472 0.0151 
Estimated LV mass, g 0.84 ± 0.04 b 1.11 ± 0.09 ab 1.25 ± 0.09 a 1.01 ± 0.05 ab 0.0411 0.84 0.0017 
Heart wet weight, mg/mm 26.5 ± 0.9 b 25.4 ± 0.6 b 30.1 ± 1.4 a 25.6 ± 0.5 b 0.05 0.0055 0.08 
LV wet weight, mg/mm 20.5 ± 0.4 b 18.8 ± 0.5 b 22.7 ± 0.8 a 19.8 ± 0.4 b 0.007 0.0002 0.29 
RV wet weight, mg/mm 4.7 ± 0.2 4.4 ± 0.2 4.6 ± 0.2 4.3 ± 0.2 0.62 0.14 1 
LV stiffness constant, κ 22.9 ± 0.4 b 24.6 ± 0.9 b 29.3 ± 0.5 a 25.1 ± 1.0 b <0.0001 0.11 0.0005 
LV interstitial collagen, %  5.8 ± 0.5 b 4.8 ± 0.9 b 18.4 ± 0.8 a 13.5 ± 0.5 b 0.0212 0.0025 <0.0001 
* Data not available; LVIDd = left ventricular internal diameter in diastole; LVPWd = left ventricular posterior wall thickness in 
diastole; LV = left ventricle; RV = right ventricle; E:A = early:late (or atrial) velocity through the mitral valve. Data are presented as the 
mean ± SEM, n = 8–9. Means without a common letter in rows are significantly different at p < 0.05. 
Increased infiltration of inflammatory cells was observed in H left ventricle, together with increased 
collagen deposition compared to C rats (Figure 2). H diet-fed rats showed hypertrophy of 
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3.3. Liver Structure and Function 
H rats had increased liver wet weight compared to C rats (Table 1). N normalised liver wet weight 
in H rats. H rats showed increased infiltration of inflammatory cells and increased deposition of 
collagen around the blood vessels in liver sections compared to C rats (Figure 4). N reduced 
inflammation and decreased collagen deposition in the liver of H rats. H rats increased deposition of 
fat droplets in liver, which was reduced by N (Figure 4). H rats increased plasma activity of aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) compared to C rats; the increases were 
normalised by N (Table 2). 
Figure 4. Haematoxylin and eosin staining of liver (×20) showing fat deposition in C (A), 
CN (B) H (C), HN (D) rats (fd, fat droplets; pv, portal vein (upper panel)) and ×40 for  
C (E), CN (F) H (G), HN (H) rats (middle panel). Milligan’s trichrome staining of the liver 
section (×20) showing collagen as darker blue region in C (E), CN (F), H (G), HN (H) 
rats; pvc, portal vein collagen (lower panel). 
 
Mitochondrial respiration (state 3, state 4 and uncoupled respiration rates, respiratory control ratio 
(RCR)) examined in isolated liver mitochondria using the flavin adenine dinucleotide (FAD)-linked 
substrate, succinate, showed decreased state 3 respiration in H rats (Table 4). Consequently, RCR was 
decreased for succinate plus rotenone (Table 4). N normalised state 3 respiration in H rats (Table 4). 
The high RCR values (Table 4) suggest that the structural and functional integrity of the mitochondrial 
preparations was preserved throughout these experiments.  
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Table 4. Succinate-dependent respiratory parameters of isolated liver mitochondria. 
Respiratory parameter C CN H HN 
p Value 
Diet Treatment Interaction 
Succinate + Rotenone-dependent 
State 3, nmol/min/mg protein 121.8 ± 15.6 a 120.6 ± 17.3 a 55.7 ± 6.6 b 111.4 ± 2.8 a 0.0069 0.0394 0.0324 
State 4, nmol/min/mg protein 19.2 ± 3.2 22.8 ± 2.0 17.4 ± 1.2 26.7 ± 3.4 0.71 0.0343 0.32 
RCR 6.8 ± 1.0 a 5.6 ± 1.1 ab 3.2 ± 0.3 b 4.5 ± 0.6 ab 0.0108 0.95 0.14 
Data are presented as the mean ± SEM, n = 3–5. RCR = respiratory control ratio. Means without a common letter in rows are 
significantly different at p < 0.05. 
4. Discussion 
Chronic feeding of a diet rich in simple carbohydrates and saturated fats induces the signs of 
metabolic syndrome in rats [11], with some or all signs being reversed when natural compounds from 
foods, including flavonoids, such as rutin and quercetin, are added to the diet [12,13]. This study 
showed that naringin produces similar responses to rutin and quercetin in high carbohydrate, high  
fat-fed rats. Our results suggest that several mechanisms may contribute to the reversal of signs, 
including reduced inflammatory cell infiltration, reduced oxidative stress, lowered plasma lipid 
concentrations and improved liver mitochondrial function.  
Metabolic syndrome is a collection of risk factors for cardiovascular disease. Naringin showed a 
range of properties that help protect the cardiovascular system, including antihypertensive,  
lipid-lowering, insulin-sensitising, anti-oxidative and anti-inflammatory properties [17]. Naringin 
prevented the age-related increase in systolic blood pressure in stroke-prone spontaneously 
hypertensive rats, increased nitric oxide production, improved endothelial function and decreased 
cerebral thrombotic tendency [18]. Further, naringin prevented oxidative stress in the hearts of rats 
with isoprenaline-induced myocardial infarction [19].  
Obesity, an important component of metabolic syndrome, is a chronic low-grade inflammatory 
condition leading to adipocyte differentiation and growth in adipose tissues [20]. In mice fed a high fat 
diet, naringin decreased visceral adiposity and lowered plasma lipid concentrations, probably by 
activation of AMP kinase [9]. Naringin was more effective as an anti-inflammatory compound than 
indomethacin in the air pouch model of inflammation [21]. The increased production of inflammatory 
cytokines in rats treated with streptozotocin and a high fat diet was reversed by chronic treatment for 
four weeks with naringin (50 mg/kg) [22]. Naringenin, the aglycone of naringin produced by colonic 
bacteria before absorption, induced growth arrest, apoptosis and lipolysis in a cell line of human  
pre-adipocytes, in contrast to naringin [23]. In the high carbohydrate, high fat dietary model, we have 
shown that both the closely related flavonoid, rutin, and its aglycone, quercetin, decreased abdominal 
fat pads [12,13], similar to naringin in this study.  
Insulin resistance/hyperglycaemia and hyperlipidaemia are two of the diagnostic criteria for 
metabolic syndrome. In type 2 diabetic db/db mice, naringin prevented the progression of 
hyperglycaemia by increasing hepatic glycolysis and lowering hepatic gluconeogenesis [24]. Naringin 
(40 mg/kg in rats) effectively inhibited dipeptidyl peptidase-IV in vivo, lowering blood glucose and 
increasing blood insulin concentrations [25]. Regulation of glucose-regulating enzymes, such as 
phosphoenolpyruvate carboxykinase and glucose-6-phosphotase following activation of AMP kinase 
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by naringin, reduced plasma blood glucose concentrations in mice fed a high fat diet [9]. In these high 
fat-fed mice, naringin lowered lipid synthesis, increased fatty acid oxidation, reversed adipocyte 
hypertrophy and decreased hepatic steatosis [9]. Further, naringin lowered cholesterol biosynthesis in 
rats fed a high fat and high cholesterol diet [26]. However, treatment of moderately 
hypercholesterolaemic men and women with naringin 500 mg/day did not change plasma cholesterol 
concentrations [27], showing the difficulty of extrapolating rat results to humans.  
Liver function may be improved in naringin-treated rats by decreased lipid peroxidation in 
diabetes [28], improvement of hepatic insulin signalling by naringenin [7] and improved liver structure 
and function, as with the closely related flavonoids, rutin [12] and quercetin [13]. Liver mitochondrial 
function was compromised in the liver of high fat-fed rats [29]. Transcriptional regulators of 
mitochondria are important in lipid metabolism and steatosis in liver. Naringin increased PPARγ 
protein expression, a transcriptional regulator of mitochondrial function, and prevented steatosis in 
diabetic male rats fed a high fat diet, probably by decreasing the expression of liver X receptor (LXR) 
and sterol regulatory element-binding protein (SREBP)-1c and SREBP-1a in liver [8]. In our study, 
naringin improved the respiratory function of isolated mitochondria from liver, suggesting 
improvement of mitochondrial function and lipid metabolism.  
The low water solubility limits the bioavailability of flavonoids that depend upon the efficiency of 
their transfer through the brush border and the capacity of the intestine to secrete conjugated 
metabolites [30]. The colon microflora hydrolysed naringin to naringenin, which is then absorbed from 
the colon to increase apparent bioavailability [31]. The ingestion of naringenin from capsules or 
naringin from grapefruit juice (135–199 mg naringenin equivalent) led to peak plasma concentrations 
of 6.0–7.3 μmol/L [32,33]. Commercial grapefruit juice ingestion in healthy volunteers showed peak 
plasma concentrations ranging from 0.3 to 1.5 μmol/L [34].  
One potential mechanism of action of polyphenols, such as naringin and naringenin, involves 
changes in the gastrointestinal microbial population. This population has been implicated in human 
disease states, including obesity [35], with polyphenols being both substrates for microbial 
biochemical pathways and modulators of bacterial growth [36]. Flavonoid aglycones, such as 
naringenin and quercetin, inhibited the growth of a wide range of gastrointestinal bacteria to a much 
greater extent than the parent glycosides [37]. These mechanisms open up a wide range of therapeutic 
possibilities for natural plant products as part of the diet [38].  
In this study, rats were administered naringin at a dose of approximately 100 mg/kg/day. This dose 
corresponds to ~1 g/day naringin in a 70 kg human based on scaling equations [39] or ~0.6 g/day 
based on body surface area comparisons between rats and humans [40]. Although the average daily 
human intake of naringin is not known, the total intake of polyphenols is ~1 g/day, with two-thirds 
being flavonoids [41]. This suggests that the dose of naringin used in this study is realistic in humans. 
This could also suggest that the dose of 500 mg/day in hypercholesterolaemic patients [27] may be too 
low to achieve full responses. Naringin is listed as “generally regarded as safe”, and chronic effects at 
doses of 1 g/day and greater have not been reported. Naringin may need to be given in divided doses, 
since the half-life of the aglycone, naringenin, produced in the distal colon, was reported as 2.3 h in  
humans [33]. 
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5. Conclusions  
Naringin was effective against the symptoms of metabolic syndrome in a diet-induced obese rat 
model. Naringin decreased inflammatory cell infiltration, lowered plasma lipids, improved oxidative 
stress and mitochondrial function as the probable mechanisms to reverse metabolic syndrome. Thus, 
citrus flavonoids, such as naringin, can be considered as a therapeutic option for the treatment of 
metabolic syndrome; clinical trials are required to establish the safety of these natural compounds. 
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